BridgeMD
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics (RAPID)
EU CTIS ID: 2024-520067-13-00
What this study is testing
To quantify the combined effect of rapid microbiology diagnostic system and locally adapted antibiotic stewardship on patients with infections due to Pseudomonas aeruginosa or carbapenemase producing Enterobacterales, which include bloodstream infections, hospital-acquired pneumonia and ventilator-associated pneumonia.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adults (above 18 years old) who are at risk of bloodstream infections, hospital-acquired pneumonia or ventilator-associated pneumonia due to Pseudomonas aeruginosa or carbapenem-resistant Enterobacterales; OR
- Adults (above 18 years old) whose blood culture bottles show Gram negative bacilli; OR
- Adults (above 18 years old) who are suspected to have hospital-acquired pneumonia or ventilator-associated pneumonia and whose respiratory samples show Gram negative bacteria on Gram stain
- Consenting criteria review and Informed consent signature
You likely can't join if
- Refractory shock or comorbid condition such that patient not expected to survive more than 48 hours; OR,
- where the bloodstream infection is thought to be related to a vascular catheter and the catheter is unable to be removed; OR
- treatment is not with the intent to cure the infection; OR,
- patient has an infection that needs prolonged antibiotic treatment (i.e more than 2 weeks); OR,
- patient is incarcerated in a correctional facility; OR,
- patients previously enrolled in this trial within the last 60 days.
See the full eligibility criteria
- Adults (above 18 years old) who are at risk of bloodstream infections, hospital-acquired pneumonia or ventilator-associated pneumonia due to Pseudomonas aeruginosa or carbapenem-resistant Enterobacterales; OR
- Adults (above 18 years old) whose blood culture bottles show Gram negative bacilli; OR
- Adults (above 18 years old) who are suspected to have hospital-acquired pneumonia or ventilator-associated pneumonia and whose respiratory samples show Gram negative bacteria on Gram stain
- Consenting criteria review and Informed consent signature
- Refractory shock or comorbid condition such that patient not expected to survive more than 48 hours; OR,
- where the bloodstream infection is thought to be related to a vascular catheter and the catheter is unable to be removed; OR
- treatment is not with the intent to cure the infection; OR,
- patient has an infection that needs prolonged antibiotic treatment (i.e more than 2 weeks); OR,
- patient is incarcerated in a correctional facility; OR,
- patients previously enrolled in this trial within the last 60 days.
- Participation in a clinical trial in which an investigational drug was administered within 30 days of screening or within the 5 half-lives of the study drug, whichever is longer. Patients for whom the proposed washout period is incompatible or inapplicable should not be enrolled in the clinical trial but should follow a standard clinical treatment plan; OR
- Treating doctor deems enrolment into the trial is not in the best interest of the patient
- Pregnant or breastfeeding
The study team makes the final eligibility decision.
Where it's taking place
- Korea, Republic of
- Malaysia
- Turkey
- Taiwan
- India
- Thailand
- Singapore
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Korea, Republic of; Malaysia; Turkey; Taiwan; India; Thailand and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.